Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer

NCT02711553 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02711553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02711553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 19, 2016
Completion date
December 31, 2026
Enrollment
309 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, biliary tract cancer, metastatic cancer